- Home
- MTNB vs POAI Comparison
MTNB vs POAI Comparison
Compare MTNB & POAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MTNB
- POAI
- Stock Information
- Founded
- MTNB 2013
- POAI 2002
- Country
- MTNB United States
- POAI United States
- Employees
- MTNB N/A
- POAI N/A
- Industry
- MTNB Biotechnology: Pharmaceutical Preparations
- POAI Industrial Specialties
- Sector
- MTNB Health Care
- POAI Health Care
- Exchange
- MTNB Nasdaq
- POAI Nasdaq
- Market Cap
- MTNB 7.9M
- POAI 7.8M
- IPO Year
- MTNB N/A
- POAI N/A
- Fundamental
- Price
- MTNB $2.36
- POAI $0.86
- Analyst Decision
- MTNB Hold
- POAI Hold
- Analyst Count
- MTNB 1
- POAI 1
- Target Price
- MTNB N/A
- POAI N/A
- AVG Volume (30 Days)
- MTNB 1.2M
- POAI 213.0K
- Earning Date
- MTNB 08-26-2025
- POAI 08-13-2025
- Dividend Yield
- MTNB N/A
- POAI N/A
- EPS Growth
- MTNB N/A
- POAI N/A
- EPS
- MTNB N/A
- POAI N/A
- Revenue
- MTNB N/A
- POAI $1,664,696.00
- Revenue This Year
- MTNB N/A
- POAI $486.27
- Revenue Next Year
- MTNB N/A
- POAI $65.50
- P/E Ratio
- MTNB N/A
- POAI N/A
- Revenue Growth
- MTNB N/A
- POAI 71.65
- 52 Week Low
- MTNB $0.47
- POAI $0.55
- 52 Week High
- MTNB $8.00
- POAI $3.06
- Technical
- Relative Strength Index (RSI)
- MTNB 86.61
- POAI 57.84
- Support Level
- MTNB $1.33
- POAI $0.71
- Resistance Level
- MTNB $1.85
- POAI $0.94
- Average True Range (ATR)
- MTNB 0.28
- POAI 0.06
- MACD
- MTNB 0.13
- POAI 0.01
- Stochastic Oscillator
- MTNB 67.88
- POAI 62.70
About MTNB Matinas Biopharma Holdings Inc.
Matinas BioPharma Holdings Inc is a clinical-stage biopharmaceutical company with a focus on identifying and developing novel pharmaceutical products. The firm's pipeline includes MAT2203, MAT2501, and others.
About POAI Predictive Oncology Inc.
Predictive Oncology Inc functions in the healthcare domain. The firm's reportable segments are Pittsburgh segment that provides services which include the application of AI using its proprietary biobank of 150,000+ tumor samples. It also creates proprietary 3D culture models used in drug development; Birmingham segment that provides contract services and research focused on solubility improvements, stability studies, and protein production; and Eagan segment that produces the FDA-cleared STREAMWAY System and associated products for automated medical fluid waste management and patient-to-drain medical fluid disposal. It derives maximum revenue from Eagan Segment.